Industries > Pharma > CAR-T Therapy Market Report 2024-2034

CAR-T Therapy Market Report 2024-2034

Forecasts by Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukaemia (ALL), Follicular Lymphoma, Multiple Myeloma (MM), Others), by Type (Abecma, Yescarta, Kymriah, Tecartus, Others), by Target Antigens (CD19/CD22, BCMA, Others), by Patient (Children, Adults, Seniors), by End-users (Hospitals, Specialty Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies

PUBLISHED: 27 June 2024
PAGES: 337
PRODUCT CODE: PHA1341
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1341 Categories: , Tag:

The CAR-T Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of CAR-T Cell Therapy in Emerging Markets Driving Market Growth

Compared to developed economies, the adoption of CAR-T cell therapy in emerging markets has been somewhat sluggish. This is mostly because these therapies come with hefty costs, and it cannot be easy to set up the required infrastructure and expertise. However, in the upcoming years, a number of variables may contribute to the growing use of CAR-T cell therapy in emerging countries. Aging populations, urbanization, and the adoption of unhealthy lifestyles are all contributing to a notable increase in cancer incidence in several emerging economies, including China, India, and Brazil. Advanced cancer therapies, such as CAR-T cell therapies, are becoming more and more necessary due to the growing burden of disease.

In emerging countries, biopharmaceutical companies are collaborating and forming partnerships with local companies and institutes to expedite the development, production, and distribution of CAR-T cell treatments. These partnerships can assist in resolving administrative and legal issues. In order to expedite the research and approval of CAR-T cell treatments, several emerging markets, like China and India, have put in place regulatory frameworks and guidelines. This could lead to increased investment and uptake.

Biopharmaceutical companies are stepping up their efforts in 2023 to leverage collaborations and strategic investments to boost the uptake of CAR-T cell treatments in emerging regions. The following are some noteworthy advancements and business expenditures in this field, particularly for 2023.

  • Novartis announced plans to build a production facility for CAR-T cell treatment in Singapore at the beginning of 2023. This plant will cater to the Asia-Pacific region, which includes developing markets such as China and India. To further research and market CAR-T cell therapies in China, the business increased its partnership with Guangzhou Bio-Ree Cell Therapy Co., Ltd.
  • Gilead Sciences and IndiaBioScience, an Indian biotechnology business, formed a strategic alliance in March 2023 to research and produce CAR-T cell treatments for the Indian market. The partnership intends to use Gilead’s CAR-T cell therapy technology and IndiaBioScience’s experience in cell therapy manufacturing to provide these medicines to patients in India.
  • In early 2023, Bristol Myers Squibb announced plans to open a CAR-T cell therapy production facility in China, working with regional businesses. Additionally, it has been claimed that the company is in talks to introduce its CAR-T cell therapies to regulatory bodies in Brazil and other Latin American countries.
  • Janssen announced in February 2023 that it will be extending its partnership with Nanjing Legend Biotech to include possible new targets and indications for the development and commercialization of CAR-T cell treatments in China. The business is also looking into joint ventures with regional businesses and organizations in other developing nations, such as Russia and India.
  • In early 2023, Poseida Therapeutics (China) reported encouraging preliminary results from its Phase 1 trial assessing P-BCMA-ALLO1, a candidate for allogeneic CAR-T cell treatment, in patients with relapsed or refractory multiple myeloma.
  • Chinese biopharmaceutical startup Cellular Biomedicine Group is developing autologous CAR-T cell treatment candidates for different cancer types in China, with hopes to start pivotal studies in 2023.

The investments above and collaborations underscore the increasing acknowledgment of the possibilities of CAR-T cell therapies in developing economies and the endeavours of biopharmaceutical corporations to get a foothold in these areas. Through creating manufacturing facilities, utilizing local expertise, and managing regulatory procedures, these firms seek to expand patients’ access to these cutting-edge cancer medicines in developing economies.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the CAR-T therapy market evolving?
  • What is driving and restraining the CAR-T therapy market?
  • How will each CAR-T therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each CAR-T therapy submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading CAR-T therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the CAR-T therapy projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of CAR-T therapy projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the CAR-T therapy market?
  • Where is the CAR-T therapy market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:

  • Our 337-page report provides 117 tables and 192 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.

Segments Covered in the Report

Indication

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukaemia (ALL)
  • Follicular Lymphoma
  • Multiple Myeloma (MM)
  • Others

Type

  • Abecma
  • Yescarta
  • Kymriah
  • Tecartus
  • Others

Target Antigens

  • CD19/CD22
  • BCMA
  • Others

End-users

  • Hospitals
  • Specialty Clinics
  • Other End-users

Patient

  • Children
  • Adults
  • Seniors

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and U.S., China, Brazil, and Singapore leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • Singapore
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • Israel
  • Rest of MEA

CAR-T Therapy Market Report 2024-2034
Need industry data? Please contact us today.

The report also includes profiles for some of the leading companies in the CAR-T Therapy Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • 2seventy bio, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Autolus Therapeutics
  • BioNTech S.E.
  • Bluebird bio Inc.
  • Bristol-Myers Squibb
  • Caribou Biosciences, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Gilead Sciences Inc.
  • GSK plc
  • Intellia Therapeutics
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.

Overall world revenue for CAR-T Therapy Market, 2024 to 2034 in terms of value the market will surpass US$1,480 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the CAR-T Therapy Market, 2024 to 2034 report help you?

In summary, our 330+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for CAR-T Therapy Market, 2024 to 2034, with forecasts for indication, type, target antigens, end-users and patient, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the CAR-T Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, Singapore, Japan, and Australia, among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for are Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen Inc., BioNTech S.E., Bluebird bio Inc., Caribou Biosciences, Inc., GSK plc, CARsgen Therapeutics Holdings Limited, Pfizer Inc., Autolus Therapeutics, Intellia Therapeutics, and 2seventy bio, Inc. of the major companies involved in the CAR-T Therapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today CAR-T Therapy Market Report 2024-2034: Forecasts by Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukaemia (ALL), Follicular Lymphoma, Multiple Myeloma (MM), Others), by Type (Abecma, Yescarta, Kymriah, Tecartus, Others), by Target Antigens (CD19/CD22, BCMA, Others), by Patient (Children, Adults, Seniors), by End-users (Hospitals, Specialty Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for CAR-T Therapy Market Report 2024-2034

    Download sample pages

    Complete the form below to download your free sample pages for CAR-T Therapy Market Report 2024-2034

      Latest Pharma news

      Cancer Immunotherapy Market

      The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

      11 June 2024

      READ

      Biological Safety Testing Market

      The global Biological Safety Testing market is projected to grow at a CAGR of 12.6% by 2034

      11 June 2024

      READ

      CAR-T Therapy Market

      The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

      11 June 2024

      READ

      Synthetic Immunology Market

      The global Synthetic Immunology market is projected to grow at a CAGR of 25.6% by 2034

      05 June 2024

      READ